tbuckley/cabot-search huggingface dataset:
Efficacy of Felbamate in Childhood Epileptic Encephalopathy (Lennox-Gastaut Syndrome)
Journal: New England Journal of Medicine (1993)

The Lennox-Gastaut syndrome is a childhood disorder characterized by multiple types of seizures, mental retardation, characteristic electroencephalographic abnormalities, and resistance to standard antiepileptic drugs. Felbamate is an investigational antiepileptic drug with a preclinical profile that suggests it would be effective in patients with multiple types of seizures. In controlled clinical trials, felbamate was superior to placebo in reducing the frequency of refractory partial-onset seizures.
BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
Authors: Brian Bergmark, Deepak Bhatt, Philippe Steg, Christina Fanola, Ofri Mosenzon, Itamar Raz, Eugene Braunwald, Benjamin Scirica
Journal: Journal of the American College of Cardiology (2017)
Exosomes isolation and characterization in non small cell lung carcinoma patients: Proof of concept study.
Authors: Christian D. Rolfo, Marco Giallombardo, Marta Castiglia, Jorge Jorge Chacartegui, Mariano Provencio, Riccardo Alessandro, Anna Paola Carreca, Pilar Roca, Jordi Oliver, Isabel Bover, Jan P. Van Meerbeeck, Antonio Russo, Marc Peeters, Patrick Pauwels
Journal: Journal of Clinical Oncology (2015)

11101 Background: The liquid biopsy is a noninvasive tool that could change the vision of diagnostic, prognostic and predictive analysis in oncology. In the liquid biopsy potential blood-based biomarkers such as exosomes could be determinate. These biological nanovescicles (40-100 nm) are involved in regulation of tumor progression and it was demonstrated that they transport miRNAs. miRNAs are shown to be key regulators of many biological processes and promising disease biomarkers. The main aim of this study is to investigate whether exosomes isolation from clinical samples (fresh plasma from NSCLC pts) is feasible. Furthermore we have investigated selected exosome miRNAs known to be related with NSCLC. Methods: A total of 12 patients with NSCLC (adenocarcinoma) were included in this pilot project, after obtaining the informed consent. Exosomes were isolated from fresh plasma by means of both Density-Gradient centrifugation and commercial isolation kit and characterized through Western-Blot (WB), NanoSight and Trasmission Electron Microscopy (TEM) analysis. The expression of selected miRNAs was performed through Real-Time PCR; miR-1228 was used as endogenous control and the fold change was calculated according the formula 2-ΔΔCq. Results: Exosomesof all samples are characterized through WB analysis for ALIX and TSG-101, known as exosome markers, and by NanoSight and TEM analysis where all samples contains particles of size between 40-100nm. Interestingly, miR-30b and -30c are up-regulated in all samples, except for one patient (adenosquamous carcinoma with a predominance of squamous cell carcinoma) in which miR-30c is down-regulated. This result might indicate that miR-30c could be related to squamous histology. In our series we have one EGFR-positive sample (exon19 deletion) that show the highest expression of miR30b, -30c, -103, -195, -221, -222. This is partially in concordance with the results from Garofalo et al., which mir-30b, -30c, -221 and -222 are regulated by EGFR and MET receptor. Conclusions: With this pilot study we have demonstrated that exosome analysis and exosomal miRNAs profiling is feasible in NSCLC this might be a noninvasive test for follow up, response and resistance to therapy.
Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14
Authors: Beatrice Drexler, Jakob Passweg, Martin Bigler, Alexandre PA Theocharides, Nathan Cantoni, Peter Keller, Georg Stuessi, Axel Rüfer, Rudolf A. Benz, Geneviève Favre, Alexandar Tzankov, Pontus Lundberg, Andrea Fuhrer, Christine Biaggi, Markus G Manz, Mario Bargetzi, Simon Mendez-Ferrer, Radek C. Skoda
Journal: Blood (2016)
ROLE OF HOSPITAL VOLUME IN IDENTIFYING LOW AND HIGH-PERFORMING SURGICAL VALVE CENTERS IN THE UNITED STATES
Authors: Rohan Khera, Ambarish Pandey, Brahmajee Nallamothu, Sandeep Das, Mark H. Drazner, Michael Jessen, Ajay Kirtane, Deepak Bhatt, James A. de Lemos, Dharam Kumbhani
Journal: Journal of the American College of Cardiology (2017)
PREDICTION TOOL FOR CONGENITAL HEART SURGERY LENGTH OF STAY
Authors: Matthew DiOrio, Catherine Allan, Ravi Thiagarajan, Kimberlee Gauvreau, Meena Nathan, Derek Mathieu, Aditya Kaza, James Dinardo, Jean Connor, John Mayer, Puja Banka, Jason Thornton, John Triedman, Lisa Bergersen
Journal: Journal of the American College of Cardiology (2017)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Authors: Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, Takashi Ura, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Taroh Satoh, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu, Yuichiro Doki, Yuko Kitagawa
Journal: The Lancet Oncology (2017)
FREQUENCY AND PREDICTORS OF CHOLESTEROL GOAL ATTAINMENT IN PATIENTS WITH CORONARY HEART DISEASE: RESULTS FROM THE DYSLIPIDEMIA INTERNATIONAL STUDY II
Authors: Anselm K. Gitt, Dominik Lautsch, Martin Horack, Kian Keong Poh, Philippe Brudi, Larry Liu, Gaetano De Ferrari, Jean Ferrières
Journal: Journal of the American College of Cardiology (2017)
RISK STRATIFICATION PREDICTS SURVIVAL IN PATIENTS WITH LOW GRADIENT PRESERVED LEFT VENTRICULAR EJECTION FRACTION AND SEVERE AORTIC STENOSIS AFTER AORTIC VALVE INTERVENTION
Authors: Yan Fan, David Zhao, Robert Applegate, Sanjay Gandhi, Brandon Stacey, Sujethra Vasu, Min Pu
Journal: Journal of the American College of Cardiology (2017)
THE PREVALENCE OF SUBCLINICAL LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE IN MEXICAN AMERICANS: RESULTS FROM THE CAMERON COUNTY HISPANIC COHORT STUDY
Authors: Anand Prasad, Nelson Gonzalez, Malaz Mohamad, Marlene Garcia, Gordon Watt, Kristina Vatcheva, Susan Laing, Joseph McCormick, Susan Fisher-Hoch
Journal: Journal of the American College of Cardiology (2017)
Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms
Authors: Rutger Verbeek, Manjinder S. Sandhu, G. Kees Hovingh, Barbara Sjouke, Nicholas J. Wareham, Aeilko H. Zwinderman, John J.P. Kastelein, Kay-Tee Khaw, Sotirios Tsimikas, S. Matthijs Boekholdt
Journal: Journal of the American College of Cardiology (2017)
Radha Mohan Mishra
Authors: Bet Mishra
Journal: BMJ (2017)

Radha Mohan Mishra, known as “Mish” to many of his friends, was born in Cuttack, Orissa, the third of four brothers. He trained at SCB Medical College, where he was both a diligent student and very politically active; early in his time there he led a student sit-in, winning a monthly stipend for poorer students. He also excelled in sports: football, cricket, and particularly athletics. At medical school, he met the love of his life and future wife, Arati Mohanty. …
BICUSPID VERSUS TRICUSPID AORTIC VALVE STENOSIS: COMPARATIVE STUDY OF CLINICAL CHARACTERISTICS AND OUTCOMES FOLLOWING AORTIC VALVE REPLACEMENT IN AN AGE-MATCHED COHORT
Authors: Geoffrey Huntley, Jeremy Thaden, Said Alsidawi, Hector Michelena, Joseph Maleszewski, William Edwards, Sorin Pislaru, Patricia Pellikka, Naser Ammash, Kevin Greason, Youssef Maalouf, Maurice Enriquez-Sarano, Vuyisile Nkomo
Journal: Journal of the American College of Cardiology (2017)
SIROLIMUS-BASED IMMUNOSUPPRESSION MITIGATES PROGRESSION OF CARDIAC ALLOGRAFT VASCULOPATHY AND IMPROVES CARDIAC OUTCOMES AFTER HEART TRANSPLANTATION: A SINGLE CENTER 15-YEAR FOLLOW-UP STUDY
Authors: Rabea Asleh, Alexandros Briasoulis, Jonella Tilford, Woong-Gil Choi, Naveen Pereira, Brooks Edwards, Alfredo Clavell, Lyle Joyce, John Stulak, Simon Maltais, David L. Joyce, Richard Daly, Amir Lerman, Sudhir Kushwaha
Journal: Journal of the American College of Cardiology (2017)
Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells
Authors: L. Fong, B. Kavanagh, Y. Hou, S. O’Brien, J. Valiente, V. Weinberg, B. I. Rini, E. J. Small
Journal: Journal of Clinical Oncology (2007)

3001 Background: CTLA-4 is a costimulatory molecule expressed on activated T cells that delivers an inhibitory signal to these T cells. CTLA4 blockade with antibody treatment has been shown to augment T cell responses and anti-tumor immunity in animal models. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a bone marrow growth factor for antigen presenting cells, which has also been shown to enhance anti-tumor immune responses. Methods: A phase I trial in patients with metastatic, hormone refractory prostate cancer (HRPC) was undertaken to combine these immunotherapies. Sequential cohorts of 3–6 patients were treated with escalating doses (0.5, 1.5 or 3 mg/kg) of ipilimumab, a fully human anti-CTLA-4 antibody, given IV on day 1 of each 28-day cycle × 4 cycles. Patients also received GM-CSF 250 mg/m 2 /d SC on days 1–14 of the 28-day cycles. Patients were monitored for toxicity as well as for T cell activation. PSA and radiographic tests were performed at baseline and through therapy to evaluate for clinical response. Results: 24 patients have been treated. Of 6 patients treated on the highest dose level (3 mg/kg ×4), 3 (50%) had confirmed PSA declines of &gt;50%, and one of these patients had a partial response in hepatic metastases. Immune-related adverse events associated with ipilimumab treatment consisted of a grade 3 rash in 1 patient at 1.5 mg/kg, a grade 3 rash and panhypopituitarism in 1 patient at 3.0 mg/kg, and a grade 3 colitis in one patient at 3.0 mg/kg. All events were successfully managed. A dose-response relationship was seen between ipilimumab dose and effector T cell activation. Expansion of circulating CD4+ FoxP3+ regulatory T cells was also seen with treatment. Conclusions: CTLA-4 blockade combined with GM-CSF treatment induces clinical responses in HRPC. Treatment induces both the expansion of activated effector and regulatory T cells in vivo in cancer patients. Finally, CD4 and CD8 T cell activation, adverse events, and clinical responses appear to be dose-dependant. Supported by NIH SPORE P50 CA89520. No significant financial relationships to disclose.
Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
Authors: Douglas Buckner Johnson, Kimberly Brown Dahlman, Jared D. Knol, Jill Gilbert, Igor Puzanov, Julie Ann Means-Powell, Justin M. Balko, Christine Marie Lovly, Vicki Leigh Keedy, Nishitha M. Reddy, Carlos L. Arteaga, Jeffrey Alan Sosman, William Pao
Journal: Journal of Clinical Oncology (2014)

11089 Background: Oncogenic genetic alterations “drive” neoplastic cell proliferation. An increasing number of potentially actionable alterations (PAAs) can be targeted by small molecules and antibodies. Since most patients (pts) do not have PAAs detectable by conventional clinical assays, NGS may identify these targets and increase treatment options. To determine the clinical impact of extensive genetic profiling, we reviewed our experience using a targeted NGS platform (FoundationOne) in advanced cancer pts. Methods: We retrospectively assessed demographics, NGS results, and therapies received for pts undergoing targeted NGS (exonic sequencing of 236 genes and selective intronic sequencing from 19 genes) from April 2012 to August 2013. PAAs were defined as somatic genetic changes inferred to confer sensitivity to approved or investigational agents. Co-primary endpoints were the proportion of pts with PAAs uncovered by NGS and the proportion who received genotype-directed therapy (GDT). Results: Samples from 103 pts were tested; most frequently breast carcinoma (26%), head and neck cancers (23%), and melanoma (10%). Most samples (83%) harbored ≥1 PAA; 6% had no detected mutations. Identified PAAs included alterations in the following pathways: cell cycle regulation (44%), PI3K-AKT (31%), and mitogen-activated protein kinase (19%); TP53 was the most commonly altered gene (32%). With median follow up of 4.1 months, 21% received GDT. Of these, 61% were on clinical trials and 39% received approved or off-label GDT; several heavily pre-treated pts experienced significant benefit. Rationale for not administering GDT to pts with PAAs included assignment to standard therapy during follow up (35%) and clinical deterioration (13%).Additionally, a novel BRAF fusion was identified in melanoma. Conclusions: A targeted NGS panel identified PAAs in the majority of advanced cancer pts in our experience. The assay identified treatment options, facilitated enrollment in clinical trials, and identified novel PAAs. As time progresses, NGS results will be used to guide therapy in an increasing proportion of pts.
Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).
Authors: Ulrik Niels Lassen, Oliver L. Chinot, Catherine McBain, Morten Sorensen, Vibeke Andree Larsen, Maryline Barrie, Patrick Roth, Oliver Krieter, Karen Wang, Kai Habben, Jean Tessier, Angelika Lahr, Matt Whiley, Michael Weller
Journal: Journal of Clinical Oncology (2013)

2092 Background: BV inhibits VEGF and is approved for progressive GBM following prior therapy. The placental growth factor (PlGF) is a member of the VEGF family and PlGF expression has been shown to correlate with tumor stage and survival in several human malignancies. In cancer patients (pts) PlGF is up-regulated upon treatment with VEGF inhibitors. RO is a humanized IgG1 mAb directed against PlGF that has demonstrated antitumor activity in an orthotopic GBM model. Single agent RO was previously tested in advanced solid tumors. Methods: Eligibility criteria included histologically confirmed GBM with documented radiographic progression upon front line therapy, ≥18 years of age, KPS ≥70, adequate bone marrow reserve and organ function. Prior treatment with VEGF/PLGF targeted therapies was not permitted. Three to six pts were enrolled per dose level (DL), the MTD defined as the dose with DLTs ≤ 1/6 pts during 28-days of cycle 1, using CTCAE v4. Results: A total of 22 pts (16m/6f) have been enrolled in 3 DLs: RO 625mg (4 pts), 1250mg (6), and 2500mg (12) IV every 2 weeks (q2w), each in combination with BV 10mg/kg IV q2w. Median age: 58 years (range 37-72). RO serum concentrations increased proportionally, while serum exposures of BV were similar between all DLs. Two pts experienced a DLT: Meningitis G3 (1250 mg) and cerebral infarction G3 (2500 mg). Most commonly reported adverse events included hypertension (14 pts), headache (11), dysphonia (10), fatigue (6), nasopharyngitis (5), epistaxis (4), constipation (4), nausea (3), and arthralgia (3). Across all DLs tested, the overall response rate by RANO criteria was 22.7%. Conclusions: The tolerability of RO in combination with BV is acceptable; a MTD was not determined. Anti-PlGF treatment does not appear to add on clinical activity observed for single agent BV in recurrent GBM. Clinical trial information: NCT01308684.
Serum carboxyterminal telopeptide (ICTP) as a prognostic marker in bone metastases (BM) treated with bisphosphonates
Authors: L. Costa, R. Carvalho, A. G. Oliveira, M. Bicho, A. Fernandes, T. Rodrigues, S. Ali, K. Leitzel, L. Demers, A. Lipton
Journal: Journal of Clinical Oncology (2006)

10107 Background: Biochemical markers of bone turnover, such as N- and C-terminal cross-linking telopeptide of type I collagen have been evaluated as prognostic matkers in patients with BM. In one of such study, we found that ICTP was not affected by bisphosphonate (BP) therapy (Costa, et al., JCO 2002; 20:850–856). In this prospective study we analyzed whether the baseline level of ICTP was predictive of skeletal related events (SREs) as defined by: pathologic fractures (PF), radiation to treat BM (RT) or spinal cord compression (SCC); time to progression (TTP) and overall survival (OS) in patients with BM from solid tumors under BP therapy. Methods: We studied 116 BM patients, median age: 64 years; 67% females; 61% breast cancer; 19% prostate cancer; and 20% other tumor types. The x-ray pattern of BM was lytic in 54% patients, blastic in 23%, and mixed in 21%. At the time of study entry, all patients had serum ICTP levels measured with RIA reagents from Orion Diagnostica (reference range: 2.5–4.0 μg/L). A serum ICTP cutoff of 6.2 μg/L was established using the mean + 2D. The occurrence of SREs was recorded during the study and an objective evaluation of BM status was performed every 4–6 months. During the time period on study, patients received treatment with IV zoledronate (57%), IV pamidronate (28%), or more than one BP. The proportional hazards model was used to investigate the correlation of ICTP baseline level with time to first SRE (TTSRE), TTP, and OS; and Poisson regression with the skeletal morbidity rate (SMR): number of SREs/person/year. Results: The median follow-up was 21 months. 81.9% patients had ICTP level above 6.2 μg/L and the mean value of ICTP was 15.1 (SD 11.9) μg/L. During the time period on study, 38% had PF, 57% had RT, and 9.5% had SCC. Median TTSRE was 20 months and the SMR was 0.84. Median TTP was 12 months and median OS time was 29 months. ICTP levels above 6.2 μg/L were associated with increased mortality risk (hazard ratio (HR) 2.86, 95%CI 1.37–6.00, p=0.005) and increased SMR (incidence rate ratio 1.88, 95%CI 0.98–3.60, p=0.057), but not with TTP (HR 1.18, 95%CI 0.67–2.07, p=0,57) or TTSRE (HR 1.59, 95%CI 0.82–3.08, p=0.17). Conclusions: Elevated serum ICTP levels is associated with decreased survival and increased incidence of SREs in BM patients on BP therapy. No significant financial relationships to disclose.
Daily concurrent chemoradiotherapy with docetaxel (D) and cisplatin (C) using new superselective intra-arterial infusion via the superficial temporal artery (HFT method) for stage III, IV head and neck cancer—Preservation of the primary lesion
Authors: I. Tohnai, N. Fuwa, K. Mitsudo, H. Nishiguchi, T. Fukui, N. Yamamoto, M. Ueda, Y. Ito
Journal: Journal of Clinical Oncology (2006)

15513 Background: We previously developed a new method of superselective intra-arterial infusion via the superficial temporal artery (HFT method; Hattori, Fuwa and Tohnai). Our previous study involved preoperative daily concurrent radiotherapy and chemotherapy with docetaxel (D) and cisplatin (C) using the HFT method for 41 patients with stage III, IV oral cancer. Clinical effects were complete response (CR) in 29 (82.9%) and partial response (PR) in 6 (17.1%) patients and pathological effects of the resected tumor were CR in 31 (88.6%) and PR in 4 (11.4%) patients, with a 5-year cumulative survival rate (overall rate) of 78.8%. Thus, the present study investigated the effectiveness of chemoradiotherapy using the HFT method without surgery for stage III, IV oral cancer. Methods: Patients (n = 16) with stage III, IV oral cancer were treated. A new catheter was prepared by modifying a 1.35-mm diameter angiographic catheter and inserting it superselectively using a guide wire to the feeding artery of the tumor via the superficial temporal artery. Long-term catheterization is possible by this method. Radiotherapy (total dose: 60 Gy) and superselective intra-arterial infusion chemotherapy using D (total dose: 60 mg/m 2 ) and C (total dose: 100 mg/m 2 ) were concurrently performed daily. Radical neck dissection was performed after chemoradiotherapy, but the primary lesions were preserved. Results: Toxicities over grade 3 were leukopenia (6.3%), mucositis (25.0%), and dermatitis (18.8%). No infection was associated with catherization. No major complications were observed. The clinical effects were CR in 13 (81.5%) patients, with recurrences in 3 patients. Salvage operations were performed in these 3 patients. The 3-year cumulative survival rate (overall rate) of 87.5% is higher than that of conventional therapy. Conclusions: Our HFT method, unlike the Seldinger method, allows for long-term catheterization, enabling daily concurrent chemoradiotherapy to be performed. This method promises to be the strategy of choice for the treatment of stage III, IV head and neck cancer. No significant financial relationships to disclose.
Rendement des coloscopies du programme de dépistage organisé du cancer colorectal: comparaison OC-SENSOR vs. HEMOCCULT dans la région Grand Est
Authors: B Denis, J Botokeky, I Gendre, M Guerbaz, E Jafflin, C Morel, V Riviere-Simonet, MC Scandola-Guyot, M Thirion, P Perrin
Journal: Endoscopy (2017)

Le dépistage organisé du cancer colorectal (DO CCR) repose sur un nouveau test depuis mai 2015. Lors de son lancement, le discours «officiel» était qu'il permettrait de «détecter environ 2 fois plus de cancers et 2,5 fois plus d'adénomes avancés» que l'ancien. Qu'en est-il vraiment? L'enjeu est d'informer «loyalement» la population invitée, les professionnels de santé et les décideurs du rapport bénéfices/risques du dépistage proposé. Le but de cette étude était de comparer les rendements des programmes de DO CCR par Hemoccult et OC-Sensor.
LONG-TERM ADVERSE ISCHEMIC OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION AMONG PATIENTS WITH VERSUS WITHOUT PRIOR CORONARY ARTERY BYPASS GRAFTING: ANALYSIS FROM 17 RANDOMIZED TRIALS
Authors: Jamie Elizabeth Diamond, Bjorn Redfors, Philippe Genereux, Mahesh Madhavan, Ajay Kirtane, Pieter Smits, Roxana Mehran, Rupa Caprihan, Ori Ben-Yehuda, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
Quality of life in subjects who are at high risk for hereditary breast and/or ovarian cancer.
Authors: Christine Staudigl, Renate Lichtenschopf, Romana Renz, Julia Schattauer, Nadja Fritzer, Georg Pfeiler, Andreas Berger, Daphne Gschwantler-Kaulich, Christian F. Singer, Muy-Kheng Maria Tea
Journal: Journal of Clinical Oncology (2014)

e12501 Background: It is known that BRCA mutation carriers have a high risk of developing breast and/or ovarian cancer. Molecular-genetic investigation can effect quality of life, family life and cause different feelings like fear, anxiety and depression. The objective of this study was to evaluate quality of life and psychological load in this special group of patients. Methods: Quality of life, cancer specific distress and psychological strain were analyzed in form of three questionnaires (WHOQOL-BREF, IES-R, SRRS). A total of 140 women participated in this study and filled out the questionnaires prior to genetic counseling at the Medical University of Vienna, Department of OB/GYN, during October 2012 and November 2013. Results: Out of 140 patients 67 (48%) were already diagnosed with breast and/or ovarian cancer. The majority of subjects, (n = 117, 83%) are generally satisfied by their quality of life and rate their quality of life good or very good, 18 (13%) judge their quality of life neither poor nor good and just 5 (4%) feel that their quality of life is poor or very poor. Nevertheless, 57 (41%) patients feel heavily impaired in their general life because other things return the topic “cancer” to their mind. Some clients (n = 44, 31%) try to remove the issue „cancer“ from their memory. Further, 68 (49%) subjects are adversely affected from negative feelings, such as blue mood, despair, anxiety and depression, whereas 28 (20%) patients negated to have such feelings. No client was affected by a posttraumatic stress disorder. Conclusions: The results of this study shows, that high risk patients are generally satisfied by their quality of life although the issue